Allergy Therapeutics's total assets for Q2 2024 were £72.97M, an increase of 12.56% from the previous quarter. GB:AGY total liabilities were £80.12M for the fiscal quarter, a 31.09% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.